Wyślij do znajomego
RSS
google +
Wersja do druku

Wiadomości (Starzenie się)

This section on health in the EU has been created as a trustworthy gateway to a wide range of information and data on health-related issues and activities at both European, national and international level. The content is produced by the European Commission, the Member States of the EU and the European Economic Area (EEA), plus EU candidate countries; by international organisations; and by pan-European non-governmental organisations in the area of public health.

Risk factors and prodromal markers and the development of Parkinson's disease    epda.eu.com

In this three-center longitudinal, observational study, authors evaluated the specific risk for PD associated with single or combinations of risk factors and prodromal markers. In addition, they eval[...]

European Summit on Innovation for Active and Healthy Ageing, Brussels, 9-10 March 2015    europa.eu

European Commission - Innovation Union - Two day high-level Summit and exhibition organised by the European Commission to discuss how demographic change can offer new opportunities for innovation, gr[...]

UK scientists find new approach to treat Parkinson's disease    epda.eu.com

UK scientists have developed a peptide that sticks to the protein that causes Parkinson's disease, stopping it from killing brain cells. The research highlights a potential new route for slowing the [...]

Parkinson's disease (PD): EU Commission approves Xadago (safinamide) For mid-late stage PD patients    epda.eu.com

The European Commission approves the use of XADAGO as add-on to L-dopa alone or in combination with other PD medications in mid-late stage PD patients with motor fluctuations[...]

Skin may help spot Alzheimer's and Parkinson's disease    epda.eu.com

Scientists have proposed a new idea for detecting brain conditions including Alzheimer's - a skin test. Their work, which is at an early stage, found the same abnormal proteins that accumulate in the[...]

Testing the first portable system for monitoring patients with Parkinson's disease    epda.eu.com

The Technical Research Centre for Dependency Care and Autonomous Living (CETpD) of the Universitat Politècnica de Catalunya has developed a pioneering portable system for monitoring the motor status [...]

New Parkinson's campaign - Parkure - sets crowdfunding precedent    epda.eu.com

A team of experienced researchers, academics and biotechnologists joined forces under the new University of Edinburgh spin-out Parkure (http://parkure.co.uk) in order to fast-track academic research [...]

Michael J. Fox Foundation Analysis Reveals Gaps between Research Volunteers & Parkinson's Clinical Studies    epda.eu.com

A paper authored by The Michael J. Fox Foundation for Parkinson's Research (MJFF) published in the Journal of Parkinson's Disease highlights baseline findings from the first three years of operating [...]

First novel discovery of a physical predictor of freezing in Parkinson's disease    epda.eu.com

MediGait reports a study finding a simple test predicting development of freezing within two years for people with Parkinson's disease.[...]

Statins may not lower Parkinson's risk    epda.eu.com

The use of statins may not be associated with lowering risk for Parkinson's disease, according to a new study led by researchers at Penn State College of Medicine and National Institute of Environmen[...]

The cost-effectiveness of DBS in combination with best medical therapy, versus best medical therapy alone, in advanced Parkinson    epda.eu.com

The cost-effectiveness of DBS combined with BMT, versus BMT alone, was evaluated from a UK payer perspective. Individual patient-level data on the effect of DBS on PD symptom progression from a large[...]

Striatal hand in Parkinson's disease: the re-evaluation of an old clinical sign    epda.eu.com

Study findings suggest that in patients without any explanation for hand deformities other than PD, striatal hand occurs very often, and is highly specific for the side of worst PD involvement. We re[...]

New growth factor indicates possible regenerative effects in Parkinson's disease    epda.eu.com

Researchers have long sought treatments that can slow the progression of Parkinson's disease. Current treatments have for decades been only symptomatic in nature, supplying the neurotransmitter dopam[...]

New mhealth platform for Parkinson's disease management    epda.eu.com

Funded with 4.4 million Euros by the European Commission the project mHealth platform for Parkinson's Disease management (PD_Manager project), which will allow people with Parkinson to be followed by[...]

New research reveals how European Governments need to address health information gap to support healthy ageing    epda.eu.com

A new report, published today, by the International Longevity Centre UK (ILC-UK) and supported by an unrestricted grant from Pfizer, explores where consumers go to seek out health information and who[...]

Creatine Doesn't Slow Parkinson's Progression    epda.eu.com

Despite early promise and a great deal of interest in creatine monohydrate as a possible treatment for Parkinson's disease (PD), a large new double-blind, placebo-controlled trial found that this tre[...]

Breath test for Parkinson's disease    epda.eu.com

Experts believe that a simple breath test could help doctors detect and diagnose Parkinson's disease. The test looks for a unique signature of chemicals in exhaled breath.[...]

Amarantus Announces Publication of Eltoprazine Phase 2a Study for Treating Parkinson's Levodopa-Induced Dyskinesia    epda.eu.com

Amarantus BioSciences Holdings, Inc., a biotechnology company focused on developing diagnostics in neurology, and therapeutic products with the potential for orphan drug designation in the areas of n[...]

GLNT Secures Allowance Of Patent For Controlling Parkinson's Therapy In Response To Symptoms    epda.eu.com

Great Lakes NeuroTechnologies announced today they have received another allowance of claims from the U.S. Patent Office. The application covers a system and method of controlling Parkinson's therapy[...]

Great Lakes NeuroTech Pilot Studies Demonstrate Computer Guided Algorithms For Programming Deep Brain Stimulation In Parkinson's    epda.eu.com

Great Lakes NeuroTechnologies announced today they have completed two pilot studies demonstrating computer-guided algorithms for programming deep brain stimulation (DBS) in Parkinson's disease.[...]

Events - European Summit on Innovation for Active and Healthy Ageing - 9-10 March 2015, Brussels, Belgium    europa.eu

The Summit on Innovation for Active and Healthy Ageing aims to engage Europe's policy, services and market leaders to co-create a shared vision on how Europe can address the challenges and seize the [...]

Parkinson's Study Dims Ambitions for Gene Flaw Carried by Brin    epda.eu.com

Two of Roche Holding AG's experimental drugs for Parkinson's disease caused lung toxicity in monkeys, researchers said, delivering a setback to one of the most promising pathways to a new type of tre[...]

Parkinson's Vaccine: EU-Team Launches Clinical Trial    epda.eu.com

A novel Parkinson's vaccine will now be tested in a clinical Phase I trial in Austria by an EU-funded consortium. The vaccine was developed by the Austrian biotech company AFFiRiS AG and targets a pr[...]

ACADIA Pharmaceuticals Presents Caregiver Burden Data at the International Congress of Non-Motor Dysfunctions in Parkinson's Dis    epda.eu.com

Data from an analysis of Phase III studies in patients with PDP showed that treatment with NUPLAZID reduced caregiver burden compared to PDP patients on placebo.[...]

Apathy in untreated early-stage Parkinson disease: Relationship with other non-motor symptoms    epda.eu.com

Apathetic patients had significantly more severe motor symptoms (P < 0.001) and a lower cognitive status (P = 0.032) than non-apathetic patients. When considering non-motor symptoms, apathy was si[...]

Conversion between Mini-Mental State Examination, Montreal Cognitive Assessment & Dementia Rating Scale-2 scores in Parkinson's    epda.eu.com

The primary aim of this study was to apply a simple and reliable algorithm for the conversion of MoCA to MMSE scores in PD patients. A secondary aim was to apply this algorithm for the conversion of [...]

Stem cells from adult nose tissue used to cure Parkinson's disease in rats    epda.eu.com

Scientists have for the first time used adult human stem cells to cure rats with Parkinson's disease, a neurodegenerative illness that currently has no cure.[...]

Blood test aims to detect Parkinson's in early stages    epda.eu.com

Researchers have developed a blood test that they say could help neurologists detect Parkinson's disease and track the illness as it progresses.[...]

Neurologists find movement tracking device helps assess severity of Parkinson's disease    epda.eu.com

A device that measures movement and balance can effectively help assess and track the progression of Parkinson's disease, even when medications are used to reduce Parkinson's symptoms, UT Southwester[...]

Tipping point of Parkinson's Disease, discovered by Cambridge University    epda.eu.com

Scientists believe they have found the tipping point in the brain which triggers Parkinson's Disease in a breakthrough which brings hope of future therapies.[...]

Neutron beams reveal how two potential pieces of Parkinson's puzzle fit    epda.eu.com

To understand diseases like Parkinson's, the tiniest of puzzles may hold big answers. That's why a team including scientists from the National Institute of Standards and Technology (NIST) have determ[...]

New technologies to help patients with Parkinson's disease    epda.eu.com

The research group of Life Supporting Technologies from Universidad Politécnica de Madrid (UPM) has developed a decision support system for healthcare experts that helps them to manage the informatio[...]

Disorders of the Oral Cavity in Parkinson's Disease and Parkinsonian Syndromes    epda.eu.com

This paper reviews current knowledge regarding the epidemiology, pathophysiology, and treatment options of disorders of the oral cavity in Parkinson's disease patients.[...]

Structural MRI correlates of the MMSE and pentagon copying test in Parkinson's disease    epda.eu.com

Study results suggest MMSE and the pentagon item reflect brain changes which at a regional level involve mainly posterior regions. Correlates of the pentagon item were seen in the same regions where [...]

Peripheral nervous system involvement in Parkinson's disease: evidence and controversies    epda.eu.com

In this review, authors discuss the different hypotheses, as well as our perspective on open issues and controversies.[...]

Dyskinesias and motor symptoms onset in Parkinson disease    epda.eu.com

Conclusions: The partial association between the body site of motor symptoms and of LID onset likely reflects pathophysiological mechanisms underlying LID.[...]

Sensitive measures of executive dysfunction in non-demented Parkinson's disease    epda.eu.com

No significant differences between groups were observed on widely used clinical measures. The PD patients scored lower than controls on the EXAMINER Executive Composite, Cognitive Control, and Workin[...]

Rotigotine vs ropinirole in advanced stage Parkinson's disease: A double-blind study    epda.eu.com

Conclusions: Rotigotine was well tolerated at doses up to 16 mg/24 h and showed similar efficacy to ropinirole except that the application site reaction was much higher in the rotigotine group.[...]

Swallowing disturbances in Parkinson's disease: A multivariate analysis of contributing factors    epda.eu.com

Conclusions: Gender, age, disease duration and dementia all seem to contribute to the occurrence of swallowing disturbances independently. However, the role played by these factors in sub-groups of p[...]

New App Helps People with Parkinson's Monitor Their Performance    epda.eu.com

Parkinson's-focused app development company PD Me Tools is pleased to announce the release of a groundbreaking new mobile app that helps people with Parkinson's disease monitor and track their sympto[...]

The significance of motor (A)symmetry in Parkinson's disease    epda.eu.com

With increasing age and disease duration comes a clear tendency to develop a more symmetric distribution of motor features in PD. Although this change in distribution pattern is associated with more [...]

Newron initiates Phase II study of sNN0031 in patients with Parkinson's disease    epda.eu.com

Newron Pharmaceuticals S.p.A. (Newron), a research and development company focused on novel CNS and pain therapies, announced today the initiation of a Phase II study of its novel molecule sNN0031 in[...]

7 tesla magnetic resonance imaging: A closer look at substantia nigra anatomy in Parkinson's disease    epda.eu.com

This review is designed to provide a better understanding of the correspondence between the outlines and subdivisions of the SN detected using different MRI contrasts and the histological organizatio[...]

Lithium prevents parkinsonian behavioral and striatal phenotypes in an aged parkin mutant transgenic mouse model    epda.eu.com

Authors found that low-dose lithium treatment prevented motor impairment as demonstrated by the open field test, pole test, and rearing behavior. Furthermore, lithium prevented dopaminergic striatal [...]

23andMe and Genentech to Analyze Genomic Data for Parkinson's Disease    epda.eu.com

23andMe, Inc., the leading personal genetics company, today announced an agreement with Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), to generate whole genome sequencing data f[...]

Impax Pharmaceuticals Announce FDA Approval of RYTARY™ Extended-Release Capsules for the Treatment of Parkinson's disease    epda.eu.com

Impax Pharmaceuticals, a division of Impax Laboratories, Inc. (NASDAQ: IPXL), today announced that the U.S. Food and Drug Administration (FDA) approved RYTARY, an extended-release oral capsule formul[...]

MRI Correlates of Parkinson's Disease Progression: A Voxel Based Morphometry Study    epda.eu.com

Authors investigated structural brain differences between a group of early-mild PD patients at different phases of the disease and healthy subjects using voxel-based morphometry (VBM). 20 mild PD pat[...]

Parkure: Finding a cure for Parkinson's disease    epda.eu.com

Parkure is looking to raise up to £150,000 from crowdfunding, in a campaign starting on the 5th of November, to address the unmet need for a cure for the disease, which affects an estimated 127,000 p[...]

Scientists create Parkinson's disease in a dish    epda.eu.com

A team of scientists led by The New York Stem Cell Foundation (NYSCF) Research Institute successfully created a human stem cell disease model of Parkinson's disease in a dish.[...]

Long-term outcome of subthalamic nucleus deep brain stimulation for Parkinson's disease using MRI-guided & MRI-verified approach    epda.eu.com

Conclusions Study data confirm that STN-DBS, using an MRI-guided/MRI-verified technique, remains an effective treatment for motor 'off' symptoms of PD in the long term with low morbidity.[...]

A novel treatment target for Parkinson's disease    epda.eu.com

For the first time here authors propose the roles of GPR109A and its agonists including niacin in CNS pathology. Moreover they predict that the neuroprotective roles of either niacin or butyrates in [...]

Parkinson's Disease Foundation Highlights Diverse Contributions of Care Partners    epda.eu.com

As part of National Family Caregivers Month this November, the Parkinson's Disease Foundation (PDF) recognizes the diverse contributions of loved ones of people with Parkinson's disease, with its All[...]

Comparison of Psychological Symptoms & Disease-Specific Quality of Life between Early- and Typical-Onset Parkinson's Patients    epda.eu.com

Study findings showed more severe depression and more impaired emotional domain of QoL in early-onset PD patients. Depression and anxiety play an important role to worsen QoL among both EOPD and TOPD[...]

A population-based study on combined markers for early Parkinson's disease    epda.eu.com

When combining SN+ and hyposmia, PPV increased to 17.6%, with a sensitivity of 51% and a specificity of 98%. Both SN+ and hyposmia offer good enrichment towards PD and ppPD, are stable against other [...]

Abnormal functional connectivity of the amygdala is associated with depression in Parkinson's disease    epda.eu.com

The increased connectivity between limbic regions and decreased connectivity between the corticolimbic networks may reflect impaired high-order cortical regulatory effects on the emotion-related limb[...]

Quitting smoking: An early non-motor feature of Parkinson's disease?    epda.eu.com

The reduced prevalence of current smokers among PD subjects as compared to healthy controls is consistent with previous findings, suggesting a possible neuroprotective effect of smoking. However, it [...]

24 Hour Levodopa-Carbidopa Intestinal Gel May Reduce Falls And Unresponsive Freezing Of Gait In Parkinson's Disease    epda.eu.com

Result: Median 360 degree turn time improved by 54%, fall frequency score reduced from 3 to 0 at 6 months, FOG questionnaire score improved by 14% and Timed Up-and-Go 8 meter walk was unchanged.[...]

Progression of gait dysfunction in incident Parkinson's disease: Impact of medication and phenotype    epda.eu.com

This study documents the progression of gait impairment over 18 months in an incident cohort of PD with regard to phenotype and medication. Gait characteristics were measured in 121 PD and 184 contro[...]

Exercise for falls prevention in Parkinson disease    epda.eu.com

Conclusions: An exercise program targeting balance, leg strength, and freezing of gait did not reduce falls but improved physical and psychological health. Falls were reduced in people with milder di[...]

Prediagnostic presentations of Parkinson's disease in primary care: a case-control study    epda.eu.com

Interpretation: A range of prediagnostic features can be detected several years before diagnosis of Parkinson's disease in primary care. These data can be incorporated into ongoing efforts to identif[...]

Launch of 'European Physiotherapy Guideline for Parkinson's disease'    epda.eu.com

A copy of the European Physiotherapy Guideline for Parkinson's disease can now be downloaded at www.parkinsonnet.info/euguideline[...]

Global long-term study on motor & non-motor symptoms & safety of LCIG in routine care of advanced Parkinson's patients....    epda.eu.com

Conclusions: This observational, routine-care study in a large cohort of advanced PD patients supports long-term safety and efficacy of LCIG infusion including motor, non-motor and QoL improvements.[...]

Cognitive training in Parkinson's disease reduces cognitive decline in the long term    epda.eu.com

Significant time treatment effects on overall cognitive functions were found for both training groups, each compared separately to the CG (DemTect, P < 0.05).[...]

Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: Final 12-month, open-label results    epda.eu.com

LCIG's safety profile consisted primarily of AEs associated with the device/procedure, l-dopa/carbidopa, and advanced PD. LCIG was generally well tolerated and demonstrated clinically significant imp[...]

Vitamin D from different sources is inversely associated with Parkinson disease    epda.eu.com

Study data confirm the association between vitamin D deficiency and PD, and for the first time demonstrate an inverse association of 25(OH)D2 with PD. Given that 25(OH)D2 concentration is independent[...]

Launch 'European Physiotherapy Guideline for Parkinson's disease'    epda.eu.com

A copy of the European Physiotherapy Guideline for Parkinson's disease can now be downloaded at www.parkinsonnet.info/euguideline.[...]

Gardedam Therapeutics announces a crowdfunding campaign: Novel Parkinson's and Alzheimer's therapies    epda.eu.com

Gadedam Therapeutics (Gardedam) launched a crowdfunding campaign with the objective of raising $195,000 USD to support and advance its novel Parkinson's and Alzheimer's disease drug disovery efforts.[...]

Dietary fat intake and risk for Parkinson's disease    epda.eu.com

The study suggests that fat intake in general is not related to the risk for PD. The weak positive association between intake of n-6 PUFA and PD risk needs further investigation.[...]

Gait and balance in Parkinson's disease subtypes: objective measures and classification considerations    epda.eu.com

Clinical assessments of the disturbances seen in patients with the PIGD subtype are not consistent with objective measures; overlapping between the groups is seen in many objective features of gait a[...]

Mind matters: placebo enhances reward learning in Parkinson's disease    epda.eu.com

Authors found that the mere expectation of dopamine release enhanced reward learning and modulated learning-related signals in the striatum and the ventromedial prefrontal cortex. These effects were [...]

Cognitive executive impairment and dopaminergic deficits in de novo Parkinson's disease    epda.eu.com

Study findings support the hypothesis that nigrostriatal dopaminergic deficit is associated with executive impairment, but not to memory or visuospatial impairment, in early PD.[...]

Norepinephrine Deficiency in Parkinson's Disease: The Case for Noradrenergic Enhancement    epda.eu.com

In addition to reducing the consequences of deficient noradrenergic signaling, enhancement strate gies have the potential for augmenting the effects of dopaminergic therapies in PD. Furthermore, earl[...]

CHMP Recommends Approval of Xadago™ (Safinamide) to Treat Parkinson´s Disease in the EU    epda.eu.com

First New Chemical Entity (NCE) in 10 years to receive a positive opinion from CHMP for the treatment of Parkinson's disease (PD) patients[...]

Drugs for Parkinson's disease can turn patients into gamblers, sex addicts and compulsive shoppers    epda.eu.com

Drugs commonly prescribed to treat Parkinson's disease increase the risk of behaviours such as sex addiction, compulsive shopping and gambling, research has found.[...]

Functional connectivity and cognitive decline over 3 years in Parkinson disease    epda.eu.com

In this fMRI study in PD, authors demonstrated a progressive loss of resting-state functional connectivity over a period of 3 years for multiple brain regions, especially in posterior parts of the br[...]

DNA methylation of the MAPT gene in Parkinson's disease cohorts and modulation by vitamin E In Vitro    epda.eu.com

The significant effects of sex, diplotype, and brain region suggest that hypermethylation of the MAPT gene is neuroprotective by reducing MAPT expression. The effect of vitamin E on MAPT represents a[...]

Gender differences on motor and non-motor symptoms of de novo patients with early Parkinson's disease    epda.eu.com

Demographic information, motor and non-motor symptom measurements were performed by face-to-face interview using specific scales. Scores and frequencies of symptoms were compared between male and fem[...]

Presence and progression of non-motor symptoms in relation to uric acid in de novo Parkinson's disease    epda.eu.com

Conclusions: This is the first report of a relationship between serum UA and presence/progression of multiple NMS in de novo PD, providing additional evidence of the reliability of UA as a biomarker [...]

Models of α-synuclein aggregation in Parkinson's disease    epda.eu.com

In this review authors focus on α-syn aggregation in the human disorder, its genetics and the availability of experimental models. Indeed, evidences show that dopamine (DA) metabolism may be related [...]

Helicobacter Pylori infection is associated with worse severity of parkinson's disease    epda.eu.com

This is the largest cross-sectional study to demonstrate an association between HP positivity and worse PD motor severity.[...]

22 year-old director sets out to propel Parkinson's into the limelight of film festivals around the world    epda.eu.com

After already being nominated for a Grierson award, one of the most prestigious documentary awards in the UK, Sam Oldmeadow is aiming to reach as many people as possible on the topic of Parkinson's u[...]

Frequency of Cholinergic & Caudate Nucleus Dopaminergic Deficits Across the Predemented Cognitive Spectrum of Parkinson's .....    epda.eu.com

Cortical cholinergic denervation is a major neurodegeneration associated with progressive declines across the spectrum of cognitive impairment in PD and typically occurs in the context of significant[...]

Press Centre - Major contract to support new pan-EU pension fund    europa.eu

The European Commission has made a key step on the way to establishing a new pan-European pension arrangement, designed to boost research mobility in Europe. It announced today (16 December 2014) the[...]

Yumanity Therapeutics Launched to Identify and Develop New Therapies for Neurodegenerative Diseases    epda.eu.com

Company formed to Discover Disease Modifying Therapies for Alzheimer's Disease, Parkinson's Disease and Amyotrophic Lateral Sclerosis[...]

Cost of deep brain stimulation for the treatment of Parkinson's disease by surgical stimulation sites    epda.eu.com

Provider costs were similar for the 144 GPi and 130 STN patients (GPi: $138,044 vs. STN: $131,822; difference = $6,222, 95% confidence interval [CI]: $42,125 to $45,343). Societal costs were also sim[...]

EPDA Move for Change survey shows Parkinson's care standards are lagging just one in 10 patients are diagnosed by a disease ex    epda.eu.com

Care provision in Parkinson's disease is falling dismally short of the standards patients and carers have every right to expect, research across Europe indicates.[...]

Back to the basics: regular exercise matters in Parkinson's: Results from the National Parkinson Foundation registry study    epda.eu.com

Regular exercisers at baseline was associated with better QOL, mobility, and physical function, less progression of disease, less caregiver burden and less cognitive decline one year later, after con[...]

Characterizing motor and non-motor aspects of early-morning off periods in Parkinson's: An international multicenter study    epda.eu.com

Results: The results demonstrate that EMO periods are common and occur in 59.7% of subjects across all disease stages in line with other reports. However, importantly, in 88.0% of those, EMOs were fo[...]

Does a specialist unit improve outcomes for hospitalized patients with Parkinson's disease?    epda.eu.com

The general ward care (n=20) and the Specialist Parkinson's Unit care (n=24) groups had similar baseline characteristics. On the specialist unit: less Parkinson's medication was omitted (13% v 20%, p[...]

Concomitant development of hypersexuality and delusional jealousy in patients with Parkinson's disease: A case series    epda.eu.com

Discussion: Hypersexuality and delusional jealousy may occur independently in PD patients on dopamine agonist therapy, but may develop together probably reflecting a common alteration of sexuality (s[...]

Effects of cognitive training in Parkinson's Disease: a randomized controlled trial    epda.eu.com

Cognitive and affective functions can be improved by cognitive trainings in PD patients. Specific effects (e.g. on memory and working memory versus depression) seem to be dependent on the type of tra[...]

The Cognition & Emotional Well-being indices of the Parkinson's Disease Questionnaire-39: What do they really measure?    epda.eu.com

Conclusions: The PDQ-39 Cognition index may be more related to mood functioning, as opposed to cognitive functioning, and should not be considered a proxy for cognitive functioning. Future studies ar[...]

Hippocampal volume and white matter disease in the prediction of dementia in Parkinson's disease    epda.eu.com

Conclusions: Hippocampal volume is a major factor predicting the development of mild cognitive impairment and dementia in PD. White matter hyperintensity also contributes to the longitudinal cognitiv[...]

Comparison of sleep and other non-motor symptoms between SWEDDs patients and de novo Parkinson´s disease patients    epda.eu.com

Conclusions: The patients with SWEDDs have less non-motor problems than newly diagnosed untreated PD patients. Given the difficulty distinguishing between SWEDDs and early PD, identifying some of non[...]

Effects of augmented visual feedback during balance training in Parkinson's disease: A pilot randomized clinical trial    epda.eu.com

VFT proved to be a feasible and safe approach to balance therapy for patients with PD. In this proof-of-concept study VFT was not superior over conventional balance training although observed trends [...]

Freezing of Gait subtypes have different cognitive correlates in Parkinson's disease    epda.eu.com

Conclusion: Aside from pharmacological differences, unresponsive FOG is associated with executive and visuospatial dysfunction implicating frontostriatal pathways while responsive FOG is associated w[...]

Neural correlates of progressive reduction of bradykinesia in de novo Parkinson's disease    epda.eu.com

Results suggest that the ACC and the cerebellum (inferior semilunar lobule) are associated with the severity of SE. Taken together with DTI findings, the present study proposes that ACC may have an i[...]

Impulse control disorder and rapid eye movement sleep behavior disorder in Parkinson's Disease    epda.eu.com

Conclusion: In Parkinson's disease, REM Sleep Behavior Disorder is not associated with impulse control disorder. The results of this study do not support the notion that PSG-confirmed RBD and ICD sha[...]

Risk of Parkinson's disease following severe constipation: A nationwide population-based cohort study    epda.eu.com

The association between constipation at the beginning of the study and the incidence of PD was examined using a Cox regression model. Information regarding comorbidities and concomitant medications u[...]

Lucilla Bossi from Parkinson Italia honoured with Medtronic's Bakken Award    epda.eu.com

The Bakken Award recognizes outstanding individuals who, with the help of medical technology, have overcome health challenges and are now making significant contributions in their communities.[...]

Ensuring good nutritional status in patients with Parkinson's disease: challenges and solutions    epda.eu.com

The means of ensuring good nutritional status in PD range from providing adequate energy and nutrients for the body, to considering in a broader perspective, the management of motor and nonmotor symp[...]

Parkinson's Disease Severity and Use of Dopaminergic Medications    epda.eu.com

The outcomes measured at the beginning of the study showed lower disease burden for participants on initial DA monotherapy compared to those taking combined LD and DA therapy after controlling for ag[...]

Levodopa: Effect on cell death and the natural history of Parkinson's disease    epda.eu.com

This review article considers the question of whether or not levodopa is toxic in Parkinson's disease (PD). l-dopa is the most effective symptomatic treatment for PD and has provided benefit for mill[...]

Interleaved programming of subthalamic deep brain stimulation to avoid adverse effects and preserve motor benefit in Parkinson's    epda.eu.com

Interleaved stimulation (ILS) is a newer programming technique that attempts to optimize the stimulation field, improving control of symptoms while minimizing stimulation-induced adverse effects. A r[...]

Effects of cannabidiol in the treatment of patients with Parkinson's disease: An exploratory double-blind trial    epda.eu.com

Study findings point to a possible effect of CBD in improving quality of life measures in PD patients with no psychiatric comorbidities; however, studies with larger samples and specific objectives a[...]

Mendelian randomization of serum urate and Parkinson's disease progression    epda.eu.com

The study was conducted among participants in DATATOP and PRECEPT, two randomized trials among patients with early PD. The 808 patients with available DNA were genotyped for three SLC2A9 single nucle[...]

Study establishes connection between gut microbiota and Parkinson's disease    epda.eu.com

Parkinson's disease sufferers have a different microbiota in their intestines than their healthy counterparts, according to a study conducted at the University of Helsinki and the Helsinki University[...]

Acorda Announces Initiation of Phase 3 Trial of CVT-301 in Parkinson's Disease    epda.eu.com

Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced that the first patient has been enrolled in a Phase 3 study of CVT-301 for the treatment of OFF episodes in Parkinson's disease (PD). OFF episo[...]

Acorda Announces Initiation of Phase 3 Trial of CVT-301 in Parkinson's Disease    epda.eu.com

Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced that the first patient has been enrolled in a Phase 3 study of CVT-301 for the treatment of OFF episodes in Parkinson's disease (PD). OFF episo[...]

Distinguishing Idiopathic Parkinson's From Other Parkinsonian Syndromes By Breath Test    epda.eu.com

Conclusions: Exhaled breath analysis with nanoarray is a promising approach for a non-invasive, inexpensive, and portable technique for differentiation between different Parkinsonian states. A larger[...]

Anxiety in Parkinson's disease: symptom dimensions and overlap with depression and autonomic failure    epda.eu.com

Conclusion: Anxiety in PD comprises affective and somatic symptom dimensions. The affective subscale of the BAI is not influenced by motor or autonomic symptoms, and may therefore prove useful for fu[...]

Parkinson's Vaccine: EU-Team Launches Clinical Trial    epda.eu.com

A novel Parkinson's vaccine will now be tested in a clinical Phase I trial in Austria by an EU-funded consortium. The vaccine was developed by the Austrian biotech company AFFiRiS AG and targets a pr[...]

ACADIA Pharmaceuticals Presents Caregiver Burden Data at the International Congress of Non-Motor Dysfunctions in Parkinson's Dis    epda.eu.com

Data from an analysis of Phase III studies in patients with PDP showed that treatment with NUPLAZID reduced caregiver burden compared to PDP patients on placebo.[...]

Longitudinal midbrain changes in early parkinson's disease: Iron content estimated from R2*/MRI    epda.eu.com

Conclusions: High field MRI demonstrates lateral SNc abnormalities that progress over 3 years in early PD consistent with increased iron content in those with more advanced disease, corresponding to [...]

Effects of combined MAO-B inhibitors and levodopa vs monotherapy in Parkinson's disease    epda.eu.com

Study data are in agreement with (a) the Continuous Dopaminergic Stimulation (CDS) theory which states that continuous stimulation of the basal ganglia enhances motor, psychiatric and cognitive funct[...]

Mitochondrial dysfunction in Parkinson's disease: a possible target for neuroprotection    epda.eu.com

This review will discuss the evidence supporting mitochondrial dysfunction in Parkinson's disease pathology as well as treatment strategies that target the mitochondria.[...]

Beneficial effects of nicotine, cotinine and its metabolites as potential agents for Parkinson's disease    epda.eu.com

The effect of nicotine and some of its derivatives on dopaminergic neurons viability, neuroinflammation, and motor and memory functions, have been investigated using cellular and rodent models of PD.[...]

Gut microbiota are related to Parkinson's disease and clinical phenotype    epda.eu.com

Study findings suggest that the intestinal microbiome is altered in PD and is related to motor phenotype. Further studies are warranted to elucidate the temporal and causal relationships between gut [...]

Taste function in early stage treated and untreated Parkinson's disease    epda.eu.com

Study findings suggest that suprathreshold measures of taste function are influenced by PD and that this disease differentially influences taste function on anterior (CN VII) and posterior (CN IX) to[...]

Linking neuroscience with modern concepts of impulse control disorders in Parkinson's disease    epda.eu.com

Here, authors provide an overview of these recent advances, with a particular emphasis on the neurobiological correlates reported in animal models and patients along with their genetic underpinnings.[...]

Stem cells from adult nose tissue used to cure Parkinson's disease in rats    epda.eu.com

Scientists have for the first time used adult human stem cells to cure rats with Parkinson's disease, a neurodegenerative illness that currently has no cure.[...]

Controversial fetal cell transplants revived for Parkinson's trials    epda.eu.com

For the last 25 years, using fetal tissue for scientific research has largely fallen out of favor in both the European and U.S. scientific communities. One of the most publicised uses of the controve[...]

Brains in the balance: New $11.5M grant fuels University of Michigan Parkinson's disease research center to aid patients    epda.eu.com

NIH grant creates Udall Center of Excellence for Parkinson's Disease Research focused on developing a treatment to prevent falls.[...]

Levodopa therapy for Parkinson's disease: Pharmacokinetics and pharmacodynamics    epda.eu.com

The pharmacokinetics of l-dopa tend to predict some of problems that can emerge during chronic therapy, which can be linked with its irregular uptake and marked dose-by-dose variability in plasma con[...]

Pramipexole Extended-Release: A Review of Its Use in Patients with Parkinson's Disease    epda.eu.com

Head-to-head trials are needed in order to fully define the role of pramipexole ER relative to other once-daily formulations of DAs (oral ropinirole and transdermal rotigotine). Nonetheless, by reduc[...]

Resting activity in visual and corticostriatal pathways in Parkinson's disease with hallucinations    epda.eu.com

This study reveals widespread hemodynamic alterations in PD. However, within a functionally abnormal occipital lobe, those with PDVH have even lower ALFF than non-hallucinators, but have higher occip[...]

Reduction of gastrointestinal symptoms in Parkinson's disease after a switch from oral therapy to rotigotine transdermal patch:    epda.eu.com

This study suggests that a switch from oral anti-PD medications to rotigotine transdermal patch may improve existing GI symptoms among patients with PD. Additional controlled studies are needed to co[...]

Teikoku Pharma USA Announces Positive Study Results of 7-Day Patch for Parkinson's Disease    epda.eu.com

Teikoku Pharma USA announced positive results of a recently completed bioavailability (BA) study examining the delivery of TPU-002RA, a 7-day rasagiline patch, for Parkinson's disease.[...]

Gardedam Therapeutics announces a crowdfunding campaign: Novel Parkinson's and Alzheimer's therapies    epda.eu.com

Gadedam Therapeutics (Gardedam) launched a crowdfunding campaign with the objective of raising $195,000 USD to support and advance its novel Parkinson's and Alzheimer's disease drug disovery efforts.[...]

Life expectancy in the EU still on the rise: launch of EU at Glance report    europa.eu

European Commission - Press Release details page - European Commission - Statement Brussels, 03 December 2014 Joint statement by Vytenis Andriukaitis, EU Commissioner for Health and Food Safety, and[...]

Prediagnostic presentations of Parkinson's disease in primary care: a case-control study    epda.eu.com

Interpretation: A range of prediagnostic features can be detected several years before diagnosis of Parkinson's disease in primary care. These data can be incorporated into ongoing efforts to identif[...]

Endothelial dysfunction and hyperhomocysteinemia in Parkinson's disease: Flow-mediated dilation study    epda.eu.com

Levodopa (l-dopa) therapy in Parkinson's disease (PD) increases serum homocysteine levels because of its metabolism via catechol O-methyltransferase, which may lead to endothelial dysfunction.[...]

GBA-associated Parkinson's disease: Reduced survival and more rapid progression in a prospective longitudinal study    epda.eu.com

Conclusions: The mutational GBA status, rather than older age and age at onset, presents an important predictor for disease progression in this specific subgroup of PD patients.[...]

Factor analysis of The Hamilton Depression Rating Scale in Parkinson's disease    epda.eu.com

Conclusion: This analysis demonstrates that the factorial validity of the HAMD in PD is unsatisfactory. This implies that the scale is not appropriate for studying specific symptom domains of depress[...]

Dopamine transporter availability in motor subtypes of de novo drug-naïve Parkinson's disease    epda.eu.com

These results suggest that in newly diagnosed drug-naïve PD patients DAT availability might be different between ART and TD in relation to different disease severity.[...]

The American Parkinson Disease Association Awards $1.1 million in Research Grants and Continues to Lead the Way to Ease the Burd    epda.eu.com

The American Parkinson Disease Association is pleased to award research funding supporting seven Research grants to junior investigators pursuing research in Parkinson's disease, three Post-Doctoral [...]

Coordinated reset neuromodulation for Parkinson's disease: Proof-of-concept study    epda.eu.com

Results: Coordinated reset neuromodulation of the subthalamic nucleus (STN) applied to six PD patients in an externalized setting during three stimulation days induced a significant and cumulative re[...]

The prevalence of Parkinson's disease: A systematic review and meta-analysis    epda.eu.com

Authors sought to synthesize studies on the prevalence of PD to obtain an overall view of how the prevalence of this disease varies by age, by sex, and by geographic location.[...]

Parkinson's UK and Global Kinetics Corporation collaborate to provide promising new mHealth technology throughout UK    epda.eu.com

An innovative medical device designed in Australia to improve management of Parkinson's is to be made available in services in the United Kingdom, as part of a 12-month pilot project.[...]

Juncker Commission Work Programme 2015 – What to Expect for Public Health?    epha.org

November 20014 - Despite the existence of various pro-public health guidelines, Mr. Juncker's Commission Programme give cause for concern. The European Commission President Mr. Juncker and First Vice[...]

Functional connectivity and cognitive decline over 3 years in Parkinson disease    epda.eu.com

In this fMRI study in PD, authors demonstrated a progressive loss of resting-state functional connectivity over a period of 3 years for multiple brain regions, especially in posterior parts of the br[...]

Endothelial dysfunction and hyperhomocysteinemia in Parkinson's disease: Flow-mediated dilation study    epda.eu.com

Levodopa (l-dopa) therapy in Parkinson's disease (PD) increases serum homocysteine levels because of its metabolism via catechol O-methyltransferase, which may lead to endothelial dysfunction.[...]

Visual hallucinations in Parkinson's disease: Theoretical models    epda.eu.com

This review considers the leading hypothetical frameworks for visual hallucinations in Parkinson's disease, summarizing the key aspects of each in an attempt to highlight the aspects of the condition[...]

Success Stories - The Euro-Asian collaboration unravelling the mysteries of ageing    europa.eu

Much as we try to evade it, age catches us all. But are there ways to reverse or slow down the ageing process at a cellular level? An international project examining the biological changes that occur[...]

CSF biomarkers and clinical progression of Parkinson disease    epda.eu.com

Authors found evidence of a link between higher levels of αSyn at baseline and worsening of motor symptoms and cognitive speed over 2 years in PD. Increased αSyn might be a marker of more intense syn[...]

The role of the LRRK2 gene in Parkinsonism    epda.eu.com

In this review, authors discuss the pathology and clinical features which show diversity and variability of LRRK2-associated PD. In addition, they do a thorough literature review and provide theoreti[...]

Dopamine transporter imaging as a diagnostic tool for Parkinsonism and related disorders in clinical practice    epda.eu.com

DAT imaging may also have some prognostic value for disease progression. However, it has limited value in differentiating among degenerative causes of parkinsonism. Clinical assessment remains the mo[...]

Constipation is reduced by beta-blockers and increased by dopaminergic medications in Parkinson's disease    epda.eu.com

Conclusions: Beta-blockers are associated with a lower risk of constipation, while dopaminergic treatments appear to increase risk of constipation.[...]

Parkinson's nurses: a light in the darkness    epda.eu.com

This article article explores the work of Parkinson's nurses, their benefits and how Parkinson's UK supports them to care for those affected by the condition.[...]

Supporting people with Parkinson's in later life    epda.eu.com

All older people with Parkinson's will benefit from access to a specialist, comprehensive old-age assessment and nursing care that understands how symptoms can affect health and wellbeing, and is res[...]

Global investigation and meta-analysis of the C9orf72 (G4C2)n repeat in Parkinson disease    epda.eu.com

Together, these findings indicate that expansions in C9orf72 do not have a major role in the pathogenesis of PD. Testing for C9orf72 repeat expansions should only be considered in patients with PD wh[...]

Direct evidence of Parkinson pathology spread from the gastrointestinal tract to the brain in rats    epda.eu.com

In conclusion, authors here provide the first experimental evidence that different α-synuclein forms can propagate from the gut to the brain, and that microtubule-associated transport is involved in [...]

Apathy in untreated, de novo patients with Parkinson's disease: validation study of Apathy Evaluation Scale    epda.eu.com

The AES-S is a reliable and valid questionnaire for detecting apathy in PD. For screening purposes a 33/34 cut-off score is indicated, but a 38/39 cut-off score is necessary when a high specificity i[...]

Dopaminergic medication does not improve stepping responses following backward & forward balance perturbations in Parkinson's    epda.eu.com

In conclusion, dopaminergic medication does not improve underscaling of stepping responses in PD. Therefore, other interventions are needed to improve these important defense postural reactions.[...]

Neuropsychological performance in LRRK2 G2019S carriers with Parkinson's disease    epda.eu.com

Conclusion: In AJ-PD, G2019S mutation status is associated with better attention (Stroop Word Reading), executive function (Stroop Interference) and language (Category Fluency) after adjustment for P[...]

Physical activity and risk of Parkinson's disease in the Swedish National March Cohort    epda.eu.com

Study results indicate that a medium level of physical activity lowers Parkinson's disease risk.[...]

Great Lakes Neurotech enters medical device app market with Kinesia One for monitoring Parkinson's disease    epda.eu.com

Great Lakes NeuroTechnologies announced today they have successfully transitioned their Kinesia technology for objective monitoring of Parkinson's disease to an app platform.[...]

Correlation between the biochemical pathways altered by mutated parkinson-related genes and chronic exposure to manganese    epda.eu.com

The studies presented in this review attempt to describe the operative properties of the genes involved in generation of early and late onset of Parkinson's disease or Parkinson-like disorders and ho[...]

Botulinum toxin type a potentiates effect of neuromotor rehabilitation of Pisa syndrome in Parkinson: A placebo controlled study    epda.eu.com

Botulin toxin (BT) may reduce muscle hyperactivity, therefore improving CT effectiveness. Authors evaluated whether the injection of incabotulinum toxin type A (iBTA) into the hyperactive trunk muscl[...]

Applause sign in advanced Parkinson's disease    epda.eu.com

Conclusions: The applause sign is present in late stage PD and correlates with a higher degree of cognitive impairment as established with accepted clinimetric tests. A higher degree of frontal lobe [...]

Cortical volume and folding abnormalities in Parkinson's disease patients with pathological gambling    epda.eu.com

This study demonstrates that combined grey matter atrophy and reduced lGI in the OFC differentiates PD patients with PG from those without PG, suggesting that this cortical area may play a critical r[...]

Diagnostic accuracy of Parkinson's disease and atypical parkinsonism in nursing homes    epda.eu.com

In a large population of Dutch nursing home residents, 20% of diagnoses within the parkinsonian spectrum were inaccurate. Almost 9% of residents had inadvertently received a diagnosis of parkinsonism[...]

Later age at onset in Parkinson's disease over twenty years in an Italian tertiary clinic    epda.eu.com

Conclusions: Over the last two decades, age at onset of PD appeared to shift progressively towards more advanced age. However, sequential, high quality population-based incidence studies are required[...]

Glucocerebrosidase mutations in primary parkinsonism    epda.eu.com

Conclusion: GBA dysfunction is relevant for synucleinopathies, such as PD and DLB, except for MSA, in which pathology involves oligodendrocytes, and the tauopathies PSP and CBD. The risk of developin[...]

Lifetime exposure to Estrogens and Parkinson's disease in California teachers    epda.eu.com

Conclusions: These results provide some support for the hypothesis that lifelong high estrogen is protective in PD, suggesting that the level and persistence of exposure over the long term may be imp[...]

Montreal Cognitive Assessment for the screening and prediction of cognitive decline in early Parkinson's disease    epda.eu.com

Conclusions: MoCA is a reliable tool in predicting cognitive decline in early PD. A MoCA score of 26 significantly increases the risk for progressive cognitive decline.[...]

The Future of Research in Parkinson Disease    epda.eu.com

There are many unanswered questions about Parkinson disease (PD), but as a result of advances in genetics, proteomics, metabolomics, epigenetics, imaging, and other novel techniques, remarkable progr[...]

Relationships among cognitive impairment, sleep, and fatigue in Parkinson's disease using the MDS-UPDRS    epda.eu.com

Results: Of these three frequent, and often inter-twined, non-motor complications, greater daytime sleepiness and fatigue were associated with worse cognitive impairment across the full spectrum of P[...]

Which features of Parkinson's Disease Predict Earlier Exit from the Workforce?    epda.eu.com

Conclusion: Demographics, disease duration, and mental health contribute to LWF, but not motor severity. Age, gender and income contributions are difficult to modify but important to recognize. Worse[...]

Success Stories - Expanding insight into Alzheimer's disease    europa.eu

Chronic neurodegenerative diseases, such as Alzheimer's, Parkinson's and Huntington's, are all characterised by an inflammatory reaction within the brain. Until now, some of the factors behind this r[...]

Great Lakes Neurotech enters medical device app market with Kinesia One for monitoring Parkinson's disease    epda.eu.com

Great Lakes NeuroTechnologies announced today they have successfully transitioned their Kinesia technology for objective monitoring of Parkinson's disease to an app platform.[...]

Trinity scientists make breakthrough in understanding Parkinson's disease    epda.eu.com

Trinity scientists make breakthrough in understanding how parkin, a gene implicated in Parkinson's disease, controls the repair and replacement of nerve cells.[...]

Increased risk of Parkinson's disease in cataract patients: A population-based cohort study    epda.eu.com

Conclusions: Overall, this study discloses a 26% increased hazard of Parkinson's disease in cataract patients. Further studies are required to investigate whether cataracts are one of non-motor manif[...]

DNAJC13 genetic variants in parkinsonism    epda.eu.com

Conclusion: Although the contribution of rare genetic variation in DNAJC13 to parkinsonisms remains to be further elucidated, this study suggests that, in addition to p.N855S, other rare variants mig[...]

Wearing-off detection in clinical practice: The wearing off real practice Key (WORK-PD) study in Parkinson's disease    epda.eu.com

Study data from a large Italian cross-sectional sample of 532 consecutive PD patients recruited from 6 different neurological outpatient units, specializing in movement disorders, confirmed that WOQ-[...]

Neuroimaging in Parkinson disease: from research setting to clinical practice    epda.eu.com

This Review discusses the lessons learnt from decades of neuroimaging research in PD, and the promising new approaches with potential applicability to clinical practice.[...]

Clinical markers for identifying cholinergic deficits in Parkinson's disease    epda.eu.com

The combination of rapid eye movement (REM) sleep behavior disorder (RBD) symptoms and fall history showed highest diagnostic accuracy (81.1%) for predicting combined thalamic and cortical cholinergi[...]

Researchers debunk myth about Parkinson's disease    epda.eu.com

BRAIN RESEARCH - Using advanced computer models, neuroscience researchers at the University of Copenhagen have gained new knowledge about the complex processes that cause Parkinson's disease. The fin[...]

Survey reveals knowledge gaps among Parkinson's patients and caregivers    epda.eu.com

A recent survey of more than 1,500 Parkinson's disease (PD) patients, caregivers and physicians reveals that information and specialized care can help patients become more engaged in their own treatm[...]

Canadian Study of Neurological Conditions Provides New Vital Information on the Impact of Parkinson's Disease    epda.eu.com

Parkinson Society Canada is excited to share today's release of the report on The National Population Health Study of Neurological Conditions by the Public Health Agency of Canada in partnership with[...]

Fall frequency, predicting falls & participating in falls Research: Similarities among people with Parkinson's with & without Co    epda.eu.com

Fall rates (falls/person during follow-up) were similar among people with and without CI. Falls and difficulty turning were more sensitive predictors of falling in those with CI than those without: a[...]

Neurotransmitter receptor density changes in Pitx3ak mice A model relevant to Parkinson's disease    epda.eu.com

Authors demonstrated striking differential changes of neurotransmitter receptor densities for numerous receptor types and brain regions, respectively. Most prominent, a strong up-regulation of GABA r[...]

Theta burst stimulation over the supplementary motor area in Parkinson's disease    epda.eu.com

To investigate whether a period of continuous theta burst stimulation (cTBS) over the supplementary motor area (SMA) induces cortical plasticity and thus improves bradykinesia in Parkinson's disease [...]

Parkinson's disease incidence and prevalence assessment in France using the national healthcare insurance database    epda.eu.com

Conclusions: The specific and sensitive definitions of disease bracket the true values; the relatively small range indicates that the current study provides good estimations of incidence and prevalen[...]

The National Parkinson Foundation Launches CareMAP: An Online Guide to Caring for Someone with Advanced Parkinson's Disease    epda.eu.com

The National Parkinson Foundation (NPF) announced the launch of a new online guide, CareMAP, which provides practical suggestions for coping with the complex problems that arise as a result of advanc[...]

Parkure: Finding a cure for Parkinson's disease    epda.eu.com

Parkure is looking to raise up to £150,000 from crowdfunding, in a campaign starting on the 5th of November, to address the unmet need for a cure for the disease, which affects an estimated 127,000 p[...]

Effects of Endurance Exercise Training on The Motor and Non-Motor Features of Parkinson's Disease: A Review    epda.eu.com

Conclusion: Endurance exercise training improves physical conditioning in PD patients; however, to date, there is insufficient evidence to include endurance exercise training as a specific treatment [...]

Formulations of hormone therapy and risk of Parkinson's disease    epda.eu.com

The findings from this study suggest an increase in PD risk associated with esterified estrogen use combined with progestin, and no risk associated with conjugated estrogen with progestin. These find[...]

Interventions for fatigue in Parkinson's disease: A systematic review and meta-analysis    epda.eu.com

Currently insufficient evidence exists to support the treatment of fatigue in PD with any drug or nondrug treatment. Further study is required.[...]

Pooled analysis of phase III with entacapone in Parkinson's disease    epda.eu.com

Conclusions: Entacapone improved daily OFF- and ON-times by a mean of 0.8 h compared with placebo across the four pooled efficacy studies and was generally well tolerated. The results of this pooled [...]

Imaging prodromal Parkinson disease: The Parkinson Associated Risk Syndrome Study    epda.eu.com

Conclusion: Subjects with DAT deficit who do not meet criteria for a diagnosis of PD can be identified by olfactory testing. Sequential biomarker assessment may identify those at risk of PD.[...]

Global Kinetics Corporation Announces FDA Clearance of the Personal KinetiGraph™ for Assessment of Parkinson's Disease Symptoms    epda.eu.com

Global Kinetics Corporation, a leading mobile health technologies company, today announced that the U.S. Food and Drug Administration (FDA) has cleared the marketing of the company's Personal KinetiG[...]

Pallidal gap junctions-triggers of synchrony in Parkinson's disease?    epda.eu.com

In this study, confocal imaging was used to detect connexin-36, the major neural gap junction protein, in postmortem tissues of PD patients and control subjects in the putamen, subthalamic nucleus (S[...]

Cortical thinning associated with mild cognitive impairment in Parkinson's disease    epda.eu.com

Patients with MCI showed regional cortical thinning in parietotemporal regions, increased global atrophy (global cortical thinning, total gray matter volume reduction, and ventricular enlargement), a[...]

The impact of subthalamic deep brain stimulation on caregivers of Parkinson's disease patients: an exploratory study    epda.eu.com

Study results show that at 1-year FU over 50 % of the caregivers rated their subjective well-being as negative. Especially older and more depressed caregivers are at risk. These caregivers and their [...]

EuroInf: A multicenter comparative observational study of apomorphine and levodopa infusion in Parkinson's disease    epda.eu.com

Based on this open-label, nonrandomized, comparative study, authors report that, in advanced Parkinson's patients, both IJLI and Apo infusion therapy appear to provide a robust improvement in motor s[...]

Scientists create Parkinson's disease in a dish    epda.eu.com

A team of scientists led by The New York Stem Cell Foundation (NYSCF) Research Institute successfully created a human stem cell disease model of Parkinson's disease in a dish.[...]

'Pocket doctor' phone app could measure Parkinson's progression    epda.eu.com

Parkinson's disease and other degenerative motor system disorders are notoriously difficult to diagnose accurately. But now, new research has resulted in a new application that enables smartphones to[...]

KineMed Receives U.S. Patent Allowance for Noscapine to Treat ALS, Parkinson's Disease, and Diabetic Neuropathy    epda.eu.com

KineMed, Inc. today announced that the company has received a notice of allowance from the U.S. Patent and Trademark Office for the invention entitled: Compositions and Methods of Treatment Using Mod[...]

Lithium prevents parkinsonian behavioral and striatal phenotypes in an aged parkin mutant transgenic mouse model    epda.eu.com

Authors found that low-dose lithium treatment prevented motor impairment as demonstrated by the open field test, pole test, and rearing behavior. Furthermore, lithium prevented dopaminergic striatal [...]

Parkinson's disease severity levels and MDS-Unified Parkinson's Disease Rating Scale    epda.eu.com

Scores of more detailed assessments, as the MDS-UPDRS, have not been translated to a grading that allows assignment of score sections to severity levels. The objective of the present study is to dete[...]

Conversion between Mini-Mental State Examination, Montreal Cognitive Assessment & Dementia Rating Scale-2 scores in Parkinson's    epda.eu.com

The primary aim of this study was to apply a simple and reliable algorithm for the conversion of MoCA to MMSE scores in PD patients. A secondary aim was to apply this algorithm for the conversion of [...]

Complementary & Alternative Management of Parkinson's Disease: An Evidence-Based Review of Eastern Influenced Practices    epda.eu.com

Study data link the increased kinase of the G2019S-LRRK2 mutation to neuronal dysfunction and demonstrate the power of the Drosophila visual system in assaying the neurological effects of genetic dis[...]

Parkinson's Disease Foundation Highlights Diverse Contributions of Care Partners    epda.eu.com

As part of National Family Caregivers Month this November, the Parkinson's Disease Foundation (PDF) recognizes the diverse contributions of loved ones of people with Parkinson's disease, with its All[...]

Apathy in untreated early-stage Parkinson disease: Relationship with other non-motor symptoms    epda.eu.com

Apathetic patients had significantly more severe motor symptoms (P < 0.001) and a lower cognitive status (P = 0.032) than non-apathetic patients. When considering non-motor symptoms, apathy was si[...]

Head injury, α-synuclein genetic variability and Parkinson's disease    epda.eu.com

The study finds some evidence that head injury and D4S3481 or rs356165 variants jointly increase the risk of PD but little evidence of interaction.[...]

ACADIA Pharmaceuticals Receives FDA Breakthrough Therapy Designation for NUPLAZID™ (Pimavanserin) for Parkinson's Disease Psycho    epda.eu.com

ACADIA Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in neurological and related central ne[...]

Action tremor in Parkinson's disease: frequency and relationship to motor and non-motor signs    epda.eu.com

Conclusions Action tremor is a relatively frequent motor sign in patients with Parkinson's disease staging 12 on the HoehnYahr scale. Action tremor correlates with rest tremor and rigidity and may be[...]

Alpha-synuclein and tau: teammates in neurodegeneration?    epda.eu.com

Moreover, tau and alpha-synuclein appear to promote the fibrillization and solubility of each other in vitro and in vivo. This suggests that interactions between tau and alpha-synuclein form a delete[...]

Unprecedented multi-stakeholder Parkinson's disease initiative 'My PD Journey' aims to improve the lives of thousands people    epda.eu.com

The European Parkinson's Disease Association (EPDA) has launched a first-of-its-kind initiative for people with Parkinson's in Europe entitled My PD Journey.[...]

Unprecedented multi-stakeholder Parkinson's disease initiative 'My PD Journey' aims to improve the lives of thousands people    epda.eu.com

The European Parkinson's Disease Association (EPDA) has launched a first-of-its-kind initiative for people with Parkinson's in Europe entitled My PD Journey.[...]

The multi-stakeholder Parkinson's disease initiative 'My PD Journey' begins its first major research project to identify whe    epda.eu.com

The European Parkinson's Disease Association (EPDA) has launched a major research project across Europe to identify good practice and to seek out the major gaps in Parkinson's disease care that curre[...]

The multi-stakeholder Parkinson's disease initiative 'My PD Journey' begins its first major research project to identify whe    epda.eu.com

The European Parkinson's Disease Association (EPDA) has launched a major research project across Europe to identify good practice and to seek out the major gaps in Parkinson's disease care that curre[...]

Effects of Tyrosine on Parkinson's Disease: A Randomized, Double-Blind, Placebo-Controlled Trial    epda.eu.com

Study results were inconclusive as to whether an increase in plasma tyrosine has an effect on OH in subjects with PD. An increase in plasma tyrosine had no effect on BP or autonomic responses in subj[...]

Midlife migraine and late-life parkinsonism    epda.eu.com

These findings suggest there may be a common vulnerability to, or consequences of, migraine and multiple indicators of parkinsonism. Additional genetic and longitudinal observational studies are need[...]

A novel treatment target for Parkinson's disease    epda.eu.com

For the first time here authors propose the roles of GPR109A and its agonists including niacin in CNS pathology. Moreover they predict that the neuroprotective roles of either niacin or butyrates in [...]

Akinetic-Rigid and Tremor-Dominant Parkinson's Disease Patients Show Different Patterns of Intrinsic Brain Activity    epda.eu.com

Overall, study findings highlight the involvement of default mode network (DMN) and STC circuit both in AR and TD subtypes, but also underscore the importance of integrating mesolimbic-striatal and C[...]

Program for Action on Global Health, Brussels, 28 October 2014 - Draft agenda available    europa.eu

European Commission - Brussels, 28 October 2014 [...]

Changes in 'Parkinson's walk' predict dementia    epda.eu.com

Political affairs and policy Medical and pharmaceutical Resources and publications Changes in 'Parkinson's walk' predict dementia "Subtle changes in the walking pattern of Parkinson's patients could[...]

Effects of combined MAO-B inhibitors and levodopa vs monotherapy in Parkinson's disease    epda.eu.com

Study data are in agreement with (a) the Continuous Dopaminergic Stimulation (CDS) theory which states that continuous stimulation of the basal ganglia enhances motor, psychiatric and cognitive funct[...]

Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease    epda.eu.com

Twenty-six loci were identified as having genome-wide significant association; these and 6 additional previously reported loci were then tested in an independent set of 5,353 cases and 5,551 controls[...]

miRNA expression is highly sensitive to a drug therapy in Parkinson's disease    epda.eu.com

Conclusions: It is probable that miRNAs are very sensitive to drug therapy and that the effects of therapy observed may be associated with changes in the levels of these miRNAs and their target genes[...]

The evolution of mild parkinsonian signs in aging    epda.eu.com

The study reveals that gait velocity was the main predictor of persistent mild parkinsonian signs, whereas cardiovascular disease was associated with new-onset mild parkinsonian signs. These findings[...]

Dopamine transporter SLC6A3 genotype affects cortico-striatal activity of set-shifts in Parkinson's disease    epda.eu.com

This is the first study indicating that the SLC6A3/DAT1 genotype has a significant effect on fronto-striatal activation and performance in Parkinson's disease. This effect is stronger for conditions [...]

Changes in Vowel Articulation with Subthalamic Nucleus Deep Brain Stimulation in Dysarthric Speakers with Parkinson's Disease    epda.eu.com

Results suggest that STN DBS may improve articulation in dysarthric speakers with PD, in terms of range of movement. Optimization of the electrical parameters for each patient is important and may le[...]

Autonomic symptoms in Parkinson's disease    epda.eu.com

Despite a growing interest in the problem of autonomic dysfunction in PD, few studies have focused on autonomic dysfunction in PD, the patient's perspective about autonomic symptoms, and the relative[...]

The major impact of freezing of gait on quality of life in Parkinson's disease    epda.eu.com

While sleepwake disturbance and mood have a significant negative impact on HRQoL in PD, the emergence of FOG represents the most substantial predictor among patients in the earlier clinical stages of[...]

Neural Substrates of Cognitive Subtypes in Parkinson's Disease: A 3-Year Longitudinal Study    epda.eu.com

Conclusions: These results suggest that visuoperceptual impairment and the early involvement of the posterior neocortex may be risk factors for rapid symptomatic progression and dementia in PD[...]

Alternations of Mean Diffusivity of Pedunculopontine Nucleus Pathway in Parkinson's Disease Patients with Freezing of Gait    epda.eu.com

Conclusions: Based on study results, microstructural changes of pedunculopontine nucleus and connected subcortical structures are closely related with FOG in PD patients.[...]

Disclaimer

The European Commission is solely responsible for information present on EU-level websites, information present in the Portal originated by the Commission. National-level information is provided by the Member States concerned and Member States are solely responsible for the accuracy of the information. Likewise, the European Commission is not responsible for information on non-governmental organisations and international organisations websites. The European Union is committed to user privacy. Read more concerning the Legal Notice.
Further questions can be answered through the Contact page. The Health-EU portal supports principles and measures to increase the credibility of information on the net. It complies with the HONcode standard for trustworthy health information: verify here.